Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Massachusetts General Hospital Cancer Center, Boston, MA, United States



Survival: 22.2 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Boston, MA
   
Hospital: Massachusetts General Hospital Cancer Center
   
Journal: Link
   
Date: 3/2012

Description:
Patients:
This study involved women with HER2-negative locally advanced or metastatic breast cancer who were divided into two separate treatment groups. Group A had 115 patients with an average age of 55.1 years. Group B consisted of 114 patients with an average age of 54.4 years.

Treatment:
Patients in group A were treated with the biologic therapy agent sorafenib (an inhibitor of kinase proteins which are involved in cancer cell growth) and the chemotherapy agent capecitabine.

Patients in group B were treated with the chemotherapy agent capecitabine only.

Toxicities:
The most severe treatment-related toxicity in group A was grade 4 neutropenia. Grade 3 hand-foot skin reaction, diarrhea, rash, and shortness of breath were also reported.

There were two treatment-related deaths due to unspecified causes in group B. Grade 4 mucosal inflammation, neutropenia, and shortness of breath were also reported.

Results:
The median overall survival for group A was 22.2 months. For group B, the median overall survival was 20.9 months.

Support: This study was partially supported by Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals.

Correspondence: Dr. Jose Baselga; email: jbaselga@partners.org

E-mail to a Friend Email Physician More Information